🇺🇸 FDA

Company profile · Sponsor

Relay

Relay Therapeutics

RLAY · NYSE biotech CAMBRIDGE, MA, USA
Pipeline
6
Drugs
0
Patents
8

Quick answer

Relay (RLAY) is a biotech company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker RLAY
Exchange NYSE
Company type biotech
Headquarters CAMBRIDGE, MA, USA
SEC CIK 0001812364

Pipeline (6)

Search pipeline →

  1. RLY-2608

    Relay

    PIK3CA Mutation

    phase 3 small molecule active

    2 trials

  2. TRUQAP 160 mg film-coated tablets, Fulvestrant Dr. Reddy’s 250 mg Solution For Injection in Pre-Filled Syringe, RLY-2608, Fulvestrant EVER Pharma 250 mg solution for injection in pre-filled syringe, Fulvestrant Dr. Reddys 250 mg solución inyectable en jeringa precargada EFG, TRUQAP 200 mg film-coated tablets

    Relay

    PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  3. RLY-2608

    Relay

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  4. RLY-2608, RLY-2608

    Relay

    PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

    phase 2 small molecule active

    1 trial

  5. RLY-5836

    Relay

    PIK3CA Mutation

    phase 1 small molecule completed

    1 trial

  6. RLY-8161

    Relay

    NRAS Mutation

    phase 1 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12331056

    SHP2 phosphatase inhibitors and methods of use thereof

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12219327

    Substituted isoindolines as PI3K-alpha inhibitors

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12152034

    FGFR inhibitors and methods of making and using the same

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12138263

    Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12084447

    SHP2 phosphatase inhibitors and methods of use thereof

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11890281

    SHP2 phosphatase inhibitors and methods of making and using the same

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11780845

    FGFR inhibitors and methods of use thereof

    Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11701354

    Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Relay?

Relay (RLAY) is a biotech company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Relay sponsor?

We track 6 ClinicalTrials.gov-linked programs for Relay, including RLY-2608 and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Relay company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.